Abstract
ObjectivePrevious studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients.MethodsWe analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis.ResultsWithin a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes.ConclusionTogether these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.
Highlights
The American Cancer Society (ACS) predicts that in 2017, 252,710 new cases of Invasive breast cancer and 63,410 new cases of carcinoma in situ (CIS) will be diagnosed in the United Sates [1]
Within a mean follow-up time of 57.2 months in our Triple Negative Breast Cancer (TNBC) cohort, high Annexin A1 (AnxA1) expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]
High Annexin A2 (AnxA2) expression was an independent indicator of poor Overall Survival (OS) [HR, 2.66; 95% CI, 1.14-6.25], Relapse Free Survival (RFS) [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]
Summary
The American Cancer Society (ACS) predicts that in 2017, 252,710 new cases of Invasive breast cancer and 63,410 new cases of carcinoma in situ (CIS) will be diagnosed in the United Sates [1]. Cancer Institute (NCI), Centers for Disease Control and Prevention (CDCP), World Health Organization (WHO), SEER, ACS and others have detailed the risk of breast cancer nationally and internationally. Breast cancer is the second leading cause of cancer death among women, the discoveries made in research have dropped breast cancer rates significantly since 1989 [3,4,5]. This would suggest that continued strides in raising awareness of early detection, discovering innovative screening techniques, and establishing appropriate clinical recommendations to adequately diagnose and prognosticate this disease will continue to decrease the overall number of lives affected by breast cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
